Information Provided By:
Fly News Breaks for May 29, 2018
MYGN
May 29, 2018 | 14:07 EDT
Piper Jaffray analyst William Quirk said Myriad Genetics' pending acquisition of Counsyl adds several tests to Myriad's portfolio and appears " strategically sound" given the overlap of the companies' presence in the Ob/Gyn market. Quirk also sees Myriad's assumption of no reimbursement improvement as conservative given the steady improvements seen over the past several years in noninvasive prenatal testing, he tells investors. The analyst maintains a Neutral rating and $32 price target on Myriad shares.
News For MYGN From the Last 2 Days
There are no results for your query MYGN
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.